Abstract
BackgroundImmunotherapy can be associated with prolonged disease control even after cessation of treatment without the need for further cancer-directed therapy. Treatment-related adverse events (TRAEs) can also persist after discontinuation of...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have